Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 12, 2011, Pages 1441-1448

  Sheridan, James P ^a   Zhang, Ying ^a   Riester, Katherine ^b   Tang, Meina T ^a   Efros, Lyubov ^a   Shi, Jia ^a   Harris, Jeffrey ^a   Vexler, Vladimir ^a   Elkins, Jacob S ^b  

^a ABBOTT LABORATORIES   (United States)

^b BIOGEN   (United States)

Author keywords

CD56bright natural killer cells; daclizumab; immunomodulation; interleukin 2 receptor; MRI

Indexed keywords

BETA INTERFERON; CD56 ANTIGEN; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR BETA; PLACEBO;

ARTICLE; BLOOD SAMPLING; CELL COUNT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION;

EID: 82555171610     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511414755     Document Type: Article

References (14)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000 ; 343: 938-952
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2002 ; 359: 1221-1231 (Pubitemid 34304266)
3. Dendrou CA, Plagnol V, Fung E, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet. 2009 ; 41: 1011-1015
4. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007 ; 357: 851-862
5. Waldmann T, Tagaya Y, Bamford R. Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol. 1998 ; 16: 205-226 (Pubitemid 28102254)
6. Kalia V, Sarkar S, Subramaniam S, Haining WN, Smith KA, Ahmed R. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity. 2010 ; 32: 91-103
7. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci. 2006 ; 103: 5941-5946
8. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 ; 9: 381-390
9. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci. 2004 ; 101: 8705-8708 (Pubitemid 38745835)
10. Martin JF, Perry JS, Jakhete NR, Wang X, Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56bright NK cells. J Immunol. 2010 ; 185: 1311-1320
11. Saraste M, Irjala H, Airas L. Expansion of CD56bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci. 2007 ; 28: 121-126 (Pubitemid 47039837)
12. Reis EA, Athanazio DA, Lima I, et al. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int. 2009 ; 29: 469-475
13. Airas L, Saraste M, Rinta S, et al. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol. 2007 ; 151: 235-243
14. De Jager PL, Rossin E, Pyne S, et al. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain. 2008 ; 131: 1701-1711 (Pubitemid 351957464)